0
0
Sanofi’s drug Wayrilz (rilzabrutinib) has been approved by the U.S. Food and Drug Administration (FDA) on August 29, 2025, as the first Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of adults with persistent or chronic immune thrombocytopenia (ITP) who have had insufficient response to previous treatments. This novel oral therapy targets the underlying immune dysregulation driving ITP by modulating multiple immune pathways, offering a new option for over 25,000 U.S. adults affected by this rare blood disorder. The approval is grounded in the positive data from the pivotal LUNA 3 phase 3 clinical trial, which demonstrated rapid and durable platelet count responses and improvements in other symptoms of ITP compared to placebo.
Sanofi’s Wayrilz: A New Milestone in ITP Treatment
The FDA’s approval of Wayrilz marks a significant advancement in the management of immune thrombocytopenia, a complex autoimmune disorder characterized by abnormally low platelet counts that increase bleeding risk and degrade quality of life. ITP affects approximately 25,000 adults in the United States alone, many of whom have limited treatment options after failing standard therapies. Wayrilz works by inhibiting BTK, an enzyme integral to several immune system cells involved in the disease process, thereby restoring immune balance through multi-immune modulation.
The approval followed the LUNA 3 clinical trial involving 202 adults with persistent or chronic ITP who had inadequate responses to prior treatments. In this randomized, double-blind, placebo-controlled trial, patients treated with Wayrilz showed statistically significant improvements including a durable platelet response rate of 23% versus 0% in the placebo group at 24 weeks, a faster median time to first platelet response (36 days versus not reached), and prolonged duration of platelet response, indicating better disease control and symptom relief.
Expert Perspectives and Clinical Context
Caroline Kruse, President and CEO of the Platelet Disorder Support Association, highlighted the substantial burden ITP imposes physically and emotionally on patients, noting that “many symptoms are often overlooked” yet impact daily living significantly. She expressed optimism that Wayrilz will help alleviate these ongoing challenges by providing an effective treatment alternative for those who have exhausted other options.
Brian Foard, Executive Vice President and Head of Specialty Care at Sanofi, emphasized the uniqueness of Wayrilz’s mechanism and its potential to become the preferred treatment for ITP patients who have not responded well to prior therapies. This approval exemplifies Sanofi’s commitment to addressing unmet needs in rare and immunological diseases through innovative therapeutic solutions.
Implications for Public Health and Patient Care
The introduction of Wayrilz offers a promising new approach to managing ITP by targeting the fundamental immune system dysregulation rather than only addressing symptoms. For patients, this means the potential for more sustained platelet count improvement, reduced bleeding risk, and better overall quality of life. Additionally, as an oral medication, Wayrilz may provide a more convenient treatment alternative compared to existing intravenous therapies, potentially improving adherence and outcomes.
From a public health perspective, expanding therapeutic options for rare hematologic disorders like ITP is critical, given the chronic nature of the disease and the limitations of current treatments. Over 25,000 adults in the U.S. could benefit from this advance, underscoring the importance of continued research and drug development in this space.
Limitations and Balanced Considerations
While the LUNA 3 trial demonstrated significant benefits of Wayrilz, it is important to contextualize these findings within the broader clinical landscape. The durable platelet response rate, although statistically significant compared to placebo, was 23%, indicating that a majority of patients may not achieve full platelet normalization. Treatment decisions should be individualized, considering patient-specific factors and previous treatment responses.
Moreover, as with any new therapy, long-term safety and efficacy data are still being gathered. Physicians and patients should weigh benefits against potential risks and remain vigilant for adverse effects as broader clinical experience with the drug accrues.
Supporting Information and Regulatory Status
Wayrilz had previously received orphan drug designation and Fast Track status from the FDA for ITP, reflecting its role in addressing an unmet medical need in a rare disorder. It has also received orphan designations for other rare blood conditions including warm autoimmune hemolytic anemia, IgG4-related disease, and sickle cell disease, with regulatory reviews ongoing in the European Union and China.
Sanofi supports patients with access programs designed to assist with treatment navigation and affordability, enhancing the practical availability of this new medication.
Medical Disclaimer
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
